Engineered immune cells take aim at Tough-to-Treat blood cancers
NCT ID NCT04836507
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This trial investigates CRC01, a therapy made from a patient's own immune cells that are genetically modified to recognize and attack cancer cells. It is for adults with large B-cell lymphoma or B-cell acute lymphoblastic leukemia that has returned or not responded to previous treatments. Participants receive a single infusion of these engineered cells, and the study aims to find the safest dose and measure how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CRC01 (CAR T-cell therapy targeting CD19)
- What this could lead to
- If successful, this could offer a new treatment option for people with hard-to-treat B-cell cancers that have not responded to standard therapies.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not apply broadly. CAR T-cell therapy can cause serious side effects like cytokine release syndrome and neurological issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALL (ACUTE B-LYMPHOBLASTIC LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
-
The Catholic University of Korea Seoul St. Mary's Hospital
RECRUITINGSeoul, 06591, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo keep aggressive lymphoma at bay?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a 'Universal' cancer target outsmart resistant blood cancers?
- What happens years after CAR-T therapy? a study aims to find out
- Can a Chemo-Antibody combo beat a tough leukemia?